Serum concentrations of erlotinib at a dose of 25 mg daily

Journal of Thoracic Oncology

Volumn 5, Issue 8, 2010, Pages 1311-1312

  Costa, Daniel B ^a   Kobayashi, Susumu ^a   Yeo, Wee Lee ^b   Hamada, Akinobu ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB;

ADULT; AGED; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; GASTROINTESTINAL TOXICITY; GENE MUTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LETTER; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; SKIN TOXICITY; ULTRAVIOLET SPECTROSCOPY;

EID: 77955107495     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181edf55c     Document Type: Letter

References (6)

1. Yeo WL, Riely GJ, Yeap BY, et al. Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. J Thorac Oncol 2010;5:1048 -1053.
2. Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002;20:4292-4302.
3. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001;19:3267-3279.
4. Costa DB, Schumer ST, Tenen DG, et al. Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations. J Clin Oncol 2008;26:1182-1184.
5. Hamada A, Sasaki A, Saeki S, et al. Personalized medicine for non-small cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC Philadelphia, PA. AACR 2010; Abstract 3588.
6. Costa DB, Halmos B, Kumar A, et al. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med 2007;4: 1669-1679.